Navigation Links
febit to Introduce Geniom RT Analyzer(R) to U.S. Market at RNAi World Congress
Date:4/22/2008

RNA, microRNA Researchers Comprise One of the Main User Groups of febit's

Simplified and Automated Microarray Technology

MEDFORD, Mass., and HEIDELBERG, Germany, April 22 /PRNewswire/ -- febit holding gmbh today announced it will introduce the Geniom RT Analyzer(R) to the U.S. market at RNAi World Congress, which will take place April 30-May 2 in Boston.

RNA-researchers, one of the main user groups of febit's new device, will benefit from the microarray technology device's high degree of automation and flexibility. In addition, microRNA researchers will enjoy febit's recently released microarray based on Sanger miRBase-Version 11.0.

The latest product in febit's Geniom family, the Geniom RT Analyzer enables the fully automated processing of microarrays on febit's own Geniom biochips. The compact all-in-one device, which employs microfluidics, provides users with high sample throughput, excellent reproducibility, high sensitivity and a variety of applications. In addition, the product's freely programmable and precise temperature control optimizes hybridizations and enables the use of enzymatic reactions directly on the microfluidic array for signal enhancement and primer extension assays.

"We have brought together in one benchtop tool the automation of multiple processes involved with the identification and understanding of how genes work," said Cord Staehler, president and CEO of febit. "This is all about flexibility, control of experiments and time savings. Still, we provide more than a machine with the Geniom RT Analyzer. Our approach is an important combination of tools and talent to help researchers meet their needs. With the demand we're seeing for the Geniom RT Analyzer, we're expanding our U.S. sales and support team as well as moving our lab and training center to a larger facility in the Boston area."

Based on the proven Geniom technology, febit offers microarray analytics for a broad spectrum of DNA and RNA samples. The array design can be chosen from current databases or freely configured by the user. Geniom arrays are produced on demand at febit and subject to rigorous quality control before shipment to the customer.

Alternatively, researchers may prefer the Geniom One(R) System, which enables integrated microarray synthesis in the user's own laboratory. This provides an independent workflow with complete control of the microarray experiments. For utmost flexibility and maximized throughput, both instruments can be utilized in combination.

The Geniom RT Analyzer at a glance

-- Sample loading, hybridization, washing, staining and detection in one

single benchtop instrument

-- Active motion hybridization in the microchannels of the microarrays

-- Precise temperature control for optimized hybridizations

Advantages

-- One device covers the complete workflow

-- Convenient handling of microarrays

-- Enhanced reproducibility and sensitivity plus higher sample throughput

by automation

Geniom arrays are currently available for the following applications

-- microRNA profiling (latest version of Sanger miRBase; efficient

extension by additional content)

-- mRNA profiling (pathway arrays, focus arrays, signature arrays)

-- Custom microarrays produced on request according to user specifications

About febit

febit is the only company to provide technologies, products and services to effectively read, write and understand the code of life, thus facilitating a systematic understanding for customers in research, diagnostics and biosecurity markets. Geniom applies precision microfluidics to simplify and automate critical steps in making and using microarrays of high quality, providing superior time and cost efficiency. febit's applications span from genome analysis and diagnostics development to synthetic gene production and industrial biotechnology. febit currently serves the life science research market with instruments, software, consumables and services in the USA and Europe.

For further information please visit http://www.febit.com.

Contact:

febit holding gmbh Russo Partners, LLC

Eva Sterzel David Schull or Wendy Lau

Public Relations Manager +1-212-845-4271

+49 (6221) 6510-300 david.schull@russopartnersllc.com

eva.sterzel@febit.de wendy.lau@russopartnersllc.com


'/>"/>
SOURCE febit holding gmbh
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. febit First to Offer miRBase 11.0 Biochip
2. febit Forms Scientific Advisory Board
3. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
6. Shire to Introduce a New UK Listed Holding Company
7. Bluestar Silicones Introduces Three New Soft and Durable Liquid Silicone Rubber Products
8. Cyprotex Introduces New Product Line Cloe(R) Select - a Portfolio of Bespoke ADME and PK Services
9. Seduce with Mousse - Replens Introduces Intimate Options: First Personal Lubricant Mousse in Canada
10. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
11. Supelco(R) Introduces Ascentis(R) Express HILIC HPLC Columns for High-Speed and High-Efficiency Separations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... 23, 2017 Research and Markets has ... report to their offering. ... The Global Market for Bioproducts ... 2016 at a CAGR of 8.9%, This ... bioproducts into seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
(Date:2/9/2017)... The biomass boiler market report by Transparency ... market globally in terms of revenue (US$ Mn) based ... for biomass boilers has been segmented on the basis ... The market based on feedstock type, has been segmented ... energy crops, urban residues, and others. On the basis ...
Breaking Biology News(10 mins):